Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Guillen

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Frontiers in Digital Health|March 2, 2026
Defining core competencies for advanced therapy medicinal products translationElena Guillen, Ana Hidalgo-Simon
Clinical Nephrology|February 9, 2021
Aplastic crisis secondary to parvovirus B19 primoinfection as an infrequent cause of anemia in an immunocompetent, non-dialysis chronic kidney disease patientElena Guillen, Evelyn Hermida, Lida Rodas, et al.
Clinical Pharmacology and Therapeutics|December 22, 2022
A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal AntibodiesElena Guillen, Niklas Ekman, Sean Barry, et al.
Journal of Environmental Management|June 24, 2021
Recovery and applications of ammoniacal nitrogen from nitrogen-loaded residual streams: A reviewZhe Deng, Niels van Linden, Elena Guillen, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 17, 2025
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case StudyMartin Schiestl, Nivedita Roy, Michael Trieb, et al.
Cytotherapy|January 23, 2024
Academic challenges on advanced therapy medicinal products' development: a regulatory perspectiveEulalia Olesti, Yoana Nuevo, Mireia Bachiller, et al.
European Journal of Radiology|January 30, 2021
Oral hydration compared to intravenous hydration in the prevention of post-contrast acute kidney injury in patients with chronic kidney disease stage IIIb: A phase III non-inferiority study (NICIR study)Carmen Sebastià, Alfredo Páez-Carpio, Elena Guillen, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 13, 2023
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?Nadine Kirsch-Stefan, Elena Guillen, Niklas Ekman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 6, 2021
Oral hydration as a safe prophylactic measure to prevent post-contrast acute kidney injury in oncologic patients with chronic kidney disease (IIIb) referred for contrast-enhanced computed tomography: subanalysis of the oncological group of the NICIR studyCarmen Sebastià, Alfredo Páez-Carpio, Elena Guillen, et al.
Heliyon|April 25, 2023
Abattoir residues as nutrient resources: Nitrogen recycling with bone chars and biogas digestatesGerhard Soja, Anders Sörensen, Bernhard Drosg, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Frontiers in Digital Health|March 2, 2026
Defining core competencies for advanced therapy medicinal products translationElena Guillen, Ana Hidalgo-Simon
Clinical Nephrology|February 9, 2021
Aplastic crisis secondary to parvovirus B19 primoinfection as an infrequent cause of anemia in an immunocompetent, non-dialysis chronic kidney disease patientElena Guillen, Evelyn Hermida, Lida Rodas, et al.
Clinical Pharmacology and Therapeutics|December 22, 2022
A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal AntibodiesElena Guillen, Niklas Ekman, Sean Barry, et al.
Journal of Environmental Management|June 24, 2021
Recovery and applications of ammoniacal nitrogen from nitrogen-loaded residual streams: A reviewZhe Deng, Niels van Linden, Elena Guillen, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 17, 2025
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case StudyMartin Schiestl, Nivedita Roy, Michael Trieb, et al.
Cytotherapy|January 23, 2024
Academic challenges on advanced therapy medicinal products' development: a regulatory perspectiveEulalia Olesti, Yoana Nuevo, Mireia Bachiller, et al.
European Journal of Radiology|January 30, 2021
Oral hydration compared to intravenous hydration in the prevention of post-contrast acute kidney injury in patients with chronic kidney disease stage IIIb: A phase III non-inferiority study (NICIR study)Carmen Sebastià, Alfredo Páez-Carpio, Elena Guillen, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 13, 2023
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?Nadine Kirsch-Stefan, Elena Guillen, Niklas Ekman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 6, 2021
Oral hydration as a safe prophylactic measure to prevent post-contrast acute kidney injury in oncologic patients with chronic kidney disease (IIIb) referred for contrast-enhanced computed tomography: subanalysis of the oncological group of the NICIR studyCarmen Sebastià, Alfredo Páez-Carpio, Elena Guillen, et al.
Heliyon|April 25, 2023
Abattoir residues as nutrient resources: Nitrogen recycling with bone chars and biogas digestatesGerhard Soja, Anders Sörensen, Bernhard Drosg, et al.
Pageof 3